Chronic Open Angle Glaucoma (COAG) is a leading cause of preventable vision loss worldwide. In the UK, management is guided by NICE (National Institute for Health and Care Excellence) recommendations, which emphasize a stepwise, patient-centered approach to control intraocular pressure (IOP) and preserve sight.
Letโs explore the current gold-standard management plan based on the latest NICE guidelines.

๐ First-Line: Laser Over Drops
For patients newly diagnosed with COAG, 360ยฐ Selective Laser Trabeculoplasty (SLT) is now recommended as the initial treatment of choice. This shift from traditional first-line eye drops to laser aims to:
- Reduce long-term dependence on medications
- Improve adherence
- Minimize side effects from topical agents
๐ Important: Always consult with a glaucoma specialist before initiating SLT and ensure shared decision-making with the patient.
๐ง If SLT Isnโt an Option
If the patient declines SLT or it is deemed unsuitable, the next step is to start a generic prostaglandin analogue (PGA) as the first-line medication. PGAs are widely accepted for their efficacy in reducing IOP.
If the response to PGA is inadequate or poorly tolerated, consider adding or switching to:
- Beta-blockers (e.g., timolol)
- Carbonic anhydrase inhibitors (e.g., dorzolamide)
- Sympathomimetics (e.g., brimonidine)
Combinations of drops from different therapeutic classes may be necessary for sufficient IOP control.
๐ก Pro Tip: Donโt forget to assess compliance and drop instillation technique. Always demonstrate and observe how the patient uses the drops.
๐ฌ Role of Surgery in COAG
When both laser and medication fail to control IOP, surgical intervention becomes necessary.
- Repeat SLT can be considered if the initial procedureโs effect has worn off.
- Trabeculectomy with mitomycin C (MMC) is the recommended surgery for advanced COAG.
- If IOP remains uncontrolled, further surgery or cyclodiode laser may be considered.
For patients who decline surgery, SLT or medications remain viable alternatives depending on disease severity.
๐ Ongoing Monitoring is Key
Management doesnโt end with treatment. Ongoing follow-up is critical to:
- Monitor IOP trends
- Assess for visual field progression
- Adjust or escalate therapy as needed
๐ฉบ A multidisciplinary approach involving ophthalmologists, optometrists, and glaucoma nurses ensures optimal care delivery.
โ Key Takeaways
- First-line: 360ยฐ SLT over topical medications
- Pharmacological back-up: PGA โ add beta-blocker/CAI/sympathomimetic if needed
- Surgery: Indicated for advanced or uncontrolled cases
- Patient involvement and technique education are crucial throughout
- Lifelong monitoring is non-negotiable
๐ Stay updated with evidence-based ophthalmology guidelines and exam-focused content on EyeCapsule.
๐งฟ For FRCOphth aspirants, knowing these NICE guideline updates is essential for both written and oral exams.